pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
◐
Sign In
Subscribe
🐶
home
jobs
news
search
Cell Therapy · news · pharmadog
← back to Cell Therapy
News · Cell Therapy
122
stories
22d
Replimune’s twice-rejected melanoma drug prevails in FDA adcomm
fiercebiotech
22d
J&J nabs option to buy ‘in vivo’ CAR-T maker Sail for nearly $2.6B
biopharma dive
22d
J&J secures right to take the helm in up to $925M Sail CAR T pact
biospace
23d
J&J lines up $2.58B option to buy Sail, Flagship's in vivo CAR-T biotech
endpoints
23d
J&J pays Sail $785M, charting course to possible in vivo CAR-T buyout
fiercebiotech
23d
FDA advisers vote against approval of Capricor’s DMD therapy in chaotic adcomm meeting
biospace
23d
FDA reviewers vote against approval of Capricor’s DMD therapy in chaotic adcomm meeting
biospace
23d
Capricor Duchenne cell therapy voted down by FDA panel
biopharma dive
23d
Updated: FDA adcomm votes down Capricor's DMD therapy over efficacy
endpoints
23d
FDA adcomm shoots down Capricor's Duchenne cell therapy after meeting marked by statistical dispute
fiercebiotech
23d
Kyverna taps ElevateBio to secure commercial supply of autoimmune CAR-T therapy
biospace
23d
Capricor and Replimune prep for FDA adcomms, Q2 earnings roll on, Sarepta’s new leader, more
biospace
23d
STAT+: FDA expert panel recommends against approval of Capricor’s Duchenne drug
stat
23d
Vertex’s latest autoimmune TCE play involves $28M upfront to AbCellera
fiercebiotech
24d
FDA says Replimune’s melanoma data package is ‘not interpretable,’ setting up tough adcomm
biospace
25d
Capricor's DMD therapy lacks efficacy, FDA says ahead of adcomm
endpoints
25d
UPDATE: FDA disputes Capricor's claims of Phase 3 success for DMD cell therapy
biospace
25d
FDA scientists question Capricor data; Legend CEO steps down
biopharma dive
25d
Legend Biotech CEO abruptly steps down without permanent replacement
fiercebiotech
26d
Lilly, AbbVie climb aboard in vivo CAR T train—but safety remains a hurdle
biospace
26d
FDA has recommitted to adcomms—but to what end?
biospace
28d
Study of Yescarta patients reveals genetic red flags for CAR-T therapy side effects
fiercebiotech
29d
FDA panel confronting peptide controversy
stat
Jul 23, 26
Roche drops TCE for lupus, but hasn’t given up on autoimmune cell therapies
fiercebiotech
Jul 22, 26
Repligen strikes $1.5B BioLife buyout to bag cell therapy product pharmas rely on
biospace
Jul 21, 26
Agios scraps sickle cell drug
biopharma dive
Jul 21, 26
Axiom plans Hong Kong IPO, hoping to carve new path for US biotechs
biospace
Jul 20, 26
‘There is always a first’: Why US biotech Axiom will begin its IPO journey in Hong Kong
fiercebiotech
Jul 20, 26
Type 1 diabetes pipeline making ‘remarkable progress’ toward insulin independence
biospace
Jul 20, 26
How Kyverna rode CAR T’s autoimmune wave to the FDA’s door
biospace
← prev
page 2 of 5
next →
